SCCM Resource Library-A Whistle Stop Tour of Drugs!

Video Transcription

Video Summary

The speaker gives a brief overview of three rare drugs related to diabetes, hemolytic anemia, and myasthenia gravis. The first drug, terdzipetide, is a weekly subcutaneous injection used for type 2 diabetes patients. It works as a double receptor agonist of GLP-1 and GIP, increasing insulin sensitivity and delaying gastric emptying. The second drug, Mitopivate, is an oral tablet for adult patients with pyruvate kinase deficiency and hemolytic anemia. It increases pyruvate kinase activity, ATP levels, and RBC lifespan. The last drug, efgarticamode, is an IV injection for myasthenia gravis patients. It blocks the neonatal FC receptor, reducing harmful acetylcholine receptor antibodies. Monitoring glucose, hemoglobin levels, and immune system function is important while using these medications.

Asset Subtitle

Pharmacology, 2023

Asset Caption

Type: two-hour concurrent | Immunomodulation in Critical Illness: A 2023 Update (SessionID 1161720)

Meta Tag

Content Type Presentation

Knowledge Area Pharmacology

Membership Level Professional

Membership Level Select

Tag Pharmacology

Year 2023

Keywords

diabetes

hemolytic anemia

myasthenia gravis

terdzipetide

Mitopivate

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.